Table 2.
Assessment of baseline cardiac status and clinical outcomes
| Total (n = 215) | Low risk (n = 50) | High risk | ||
|---|---|---|---|---|
| Perfusion defect (−) (n = 90) | Perfusion defect (+) (n = 75) | |||
| Electrocardiography, n (%) | ||||
| LVH* | 140 (65.1) | 22 (44.0) | 64 (71.1) | 54 (72.0) |
| Pathologic Q wave*,† | 29 (13.5) | 3 (6.0) | 10 (11.1) | 16 (21.3) |
| ST wave abnormality | 121 (56.3) | 25 (50.0) | 52 (57.8) | 44 (58.7) |
| Echocardiography | ||||
| LVEF*,† | 55.0 ± 10.6 | 58.8 ± 8.4 | 56.7 ± 9.6 | 50.1 ± 11.4 |
| RWMA, n (%)*,† | 37 (17.2) | 0 (0.0) | 14 (15.6) | 23 (30.6) |
| LV geometry* | ||||
| Normal | 72 (33.5) | 27 (34.0) | 25 (27.8) | 20 (26.7) |
| Concentric hypertrophy | 113 (52.6) | 17 (34.0) | 52 (57.8) | 44 (58.7) |
| Eccentric hypertrophy | 25 (11.6) | 6 (12.0) | 9 (10.0) | 10 (13.3) |
| Concentric remodeling | 5 (2.3) | 0 (0.0) | 4 (4.4) | 1 (1.3) |
| Pulmonary hypertension*,† | ||||
| None | 177 (82.3) | 46 (92.0) | 80 (88.9) | 51 (68.0) |
| Mild | 16 (7.4) | 2 (4.0) | 3 (3.3) | 11 (14.7) |
| Moderate to severe | 22 (10.2) | 2 (4.0) | 7 (7.8) | 13 (17.3) |
| SPECT | ||||
| EF at stress† | – | – | 55.9 ± 11.5 | 49.0 ± 9.7 |
| TID | – | – | 1.04 (0.68–1.35) | 1.08 (0.22–1.64) |
| SSS† | – | – | 0 (0–8) | 4 (0–33) |
| Normal (0–4), n (%) | 81 (90.0) | 47 (62.7) | ||
| Mild (4–8), n (%) | 6 (6.7) | 12 (16.0) | ||
| Moderate–severe (≥9), n (%) | 3 (3.3) | 16 (21.3) | ||
| SRS† | – | – | 0 (0–3) | 2 (0–21) |
| SDS† | – | – | 0 (0–4) | 2 (0–12) |
| Cardiac events*,†, n (%) | ||||
| Total | 53 (24.7) | 2 (4.0) | 15 (16.7) | 36 (48.0) |
| Nonfatal ACS | 30 (14.0) | 1 (2.0) | 7 (7.8) | 22 (29.3) |
| Cardiac death | 19 (8.8) | 1 (2.0) | 7 (7.8) | 11 (14.7) |
| ADHF | 4 (1.9) | 0 (0.0) | 1 (1.1) | 3 (4.0) |
LVH, Left ventricular hypertrophy; LVEF, left ventricular ejection fraction; RWMA, regional wall motion abnormality; SPECT, single-photon emission computed tomography; TID, transient ischemic dilatation; SSS, summed stress score; SRS, summed rest score; SDS, summed difference score; ACS, acute coronary syndrome; ADHF, acute decompensated heart failure.
* P < .05 between the high- and the low-risk groups.
† P < .05 between patients without and with perfusion defect among the high-risk patients.